An Engineered Aminotransferase for the Synthesis of a Key Chiral Intermediate of Lenacapavir

14 June 2024, Version 1
This content is a preprint and has not undergone peer review at the time of posting.


We report the development of an engineered aminotransferase for the synthesis of a key chiral intermediate of the anti-HIV drug Lenacapavir. Due to the sterically demanding nature of the ketone substrate, a substrate walking approach was adopted during directed evolution to unlock desired aminotransferase activity starting from a parent template (TA25) with no observable activity for the target reaction. Introduction of 6 mutations into TA25 over 4 rounds of directed evolution led to the development of an engineered aminotransferase that affords the target chiral amine product with 90% conversion and >99% e.e. in favor of the desired S-enantiomer. The enzyme serves as a valuable template for the development of an industrial biocatalyst for the manufacture of Lenacapavir


Directed Evolution


Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.